Schrödinger builds physics-based computational software used to model molecules for drug discovery and materials science. Its platform combines molecular simulation, machine learning and enterprise workflows so biopharma and industrial R&D teams can design and prioritize compounds before wet-lab testing. Revenue comes from software licenses and subscriptions as well as collaborative research programs with life-science partners.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 54.8 | — | -43.2 | — |
| Q3 2025 | 54.3 | — | -32.8 | — |
| Q4 2025 | 87.2 | — | 32.5 | — |
| Q1 2026 | 58.6 | — | -60 | — |
| Q2 2026 | 58.9 | 7.5% | 6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: UroGen Pharma Ltd. (URGN), Vir Biotechnology, Inc. (VIR), Braveheart Bio, Inc. (BRVE), Happen, Inc. (HAPN), Personalis, Inc. (PSNL), Progress Software Corporation (PRGS)